biomed devic servic
price close busi april
medic devic heart valv therapi includ tissu
valv mechan valv repair product
sequenti us tavr growth salient
take-away accumul reiter buy
bottom line put quarter proper context like trend come
name q/q growth us tavr thu recommend accumul ew aggress
weak ew toughest y/i comp year mention
heighten expect come blow-out tavr perform see note
hour trade stock presum ww tavr
exceed consensu expect even though total revenu pro forma ep beat
forecast manag also increas sale growth guidanc vs
previous ep guidanc admittedli due
part fx tailwind lower tax rate respect import us howev
fact ew deliv anoth sequenti increas us tavr revenu q/q
let alon difficult comp look forward think deck stack
ew favor thank new tavr product launch ultra us/
eu prior centera launch europ low risk approv
us late mention compel pipelin mitral/tricuspid repair product
think gain momentum cardioband begin ramp europ
pascal eu market approv
see plenti opportun ew continu deliv double-digit growth
research suggest tavr us sever symptomat patient
think exce patient annual remain significantli under-penetrated
believ ew maintain technology/portfolio lead us ou
sapien centera tag team continu believ tmvr take
sever year deliv materi revenu contribut remain construct ew
tmvre repair program especi pascal lastli beat oper
leverag potenti drum quit time front ew deliv
produc pro forma om vs show leverag model even
without monstrou tavr beat om leverag remain key catalyst ep
stock view front remain bullish recommend investor remain
construct buy weak ew print
ew tavr busi ew tavr busi deliv result in-lin
compani expect although inflat street number toughest
overal tavr comp year especi us tavr busi report
growth tavr perform live blow-out
saw plenti evid result underli trend us tavr
market remain intact wit ew domest tavr busi deliv growth mid-
teen line overal market robust growth lower-volum center play
develop build referr base
continu augment tavr adopt continu pg
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
ew tavr busi continu note ew also announc cap approv
firm trial low-risk fda approv continu expect late
follow data present march cap program expect
commenc centera pivot also recent green-light fda
enrol expect commenc
ou procedur volum grew double-digit rang ew note minim y/i
share shift europ driven firm respect price strategi
region ew grow slightli european market believ
addit centera price premium even well ultra ce
mark approv still expect serv differenti ew
competit platform help drive share back ew court wed also note
still small japan remain fastest grow tavr region date
repres larg long-term opportun minim tavr center less
today act main current barrier robust market penetr
comp eas alongsid ultra market launch us eu prior
year end ramp centera sale europ addit small
potenti tailwind stem low-risk cap remain confid ew well
posit hit exceed tavr growth estim
tavr market dynam larg continu believ tavr market
remain highli under-penetrated stage game mani potenti
patient either undiagnos els refer treatment manag
reiter long-term tavr market outlook call expect current
ww tavr market surpass continu expans expect beyond
vis-a-vi indic expans asymptomat moder technolog
advanc open therapi patient moderate-to-
sever develop countri also emerg market long-
term current model total address us popul patient
preval american ssa primari etiolog
addit patient year old present ssa grow
see model figur within popul model patient
fall current indic low risk cohort upcom low risk
oper leverag thesi power oper leverag continu
tavr growth play regard tavr leverag om line
om leverag model evalu potenti ep upsid stem nomin
dollar growth y/i ww tavr suggest firm ep could come high
without contempl upsid current tavr revenu estim
illustr oper incom leverag model figur calcul sum-
of-part oper incom use assumpt ew oper margin
increment tavi revenu y/i expect tavr-induc margin leverag
continu beyond
structur heart pipelin updat manag provid comprehens updat
transcathet mitral tricuspid program tmtt note platform
portfolio use treat patient quarter reiter expect
launch least one new platform per year next sever year europ ew
record total cardioband mitral sale less quarter despit slower
plan integr valtech suppli chain ew maintain expect
total cardioband mitral revenu calendar sale ramp
throughout year pascal ew addit shot goal transcathet mitral
repair arena remain track ce mark approv launch europ
ew posit initi us trial later year previous report six-
month clinic result pascal highli posit demonstr great safeti
efficaci profil check continu suggest pascal repres
biomed devic servic
improv current avail mitraclip platform upcom coapt data
ultim neutral posit think could help open fmr repair
market us pascal prime gobbl share post-approv specif
replac side ew mitral portfolio manag note continu progress
cardiaq sapien platform system leverag fulli
percutan ts approach manag note time firm remain
posit platform potenti cardiaq continu deliv solid
clinic result see recent tmvr updat note tricuspid enrol
cardioband tricuspid ce mark trial complet platform track
launch europ firm process activ site
commenc ef us cardioband data mitral tricuspid expect
present pcr may manag also note forma implant
resum follow recent paus surgic mitral repair ew note recent
develop clinic complic three patient treat earli
clinic studi harpoon ew focus address root caus
issu harpoon eu market launch potenti delay result firm
previous project control launch europ follow recent receipt
ce mark
top line guidanc reiter earn guidanc rais exit in-lin
manag reiter previous state guidanc continu expect total sale
come higher end rang incorpor ew
outlook firm continu expect come high end guidanc
rang three busi unit total tavr thvt sale rang
total surgic heart revenu rang
total critic sale full year
adjust ep expect rang prior rang
increas incorpor project benefit lower tax rate
partial off-set increas plan expenditur higher tax benefit
manag guid sale rang adjust ep
figur edward result vs cg estim consensu project
biomed devic servic
deriv price target appli price-to-earnings
pro forma ep
biomed devic servic
p/e/g valuat financi metric use current median large-cap medic devic price-to-earnings multipl ex outlier med-tech comp group ep compound-annual-growth-rate forward impli ew forma oper incom growth forward p/e/g multipl price-to-earnings multipl forma mo margin leverag model sum-of-the-part busi critic savr tavi revenuerevenu base busi revenu transcathet mitral programgm increas spend fund tmvr programsoper incom base margin base tavi revenu dollar y/i itavi itavi y/i margin itavi assumpt incom sg part base biz itavitot rate addit share repurchas next yearsep ep via analysi pro cg current differenti differenti vs cg figur tavi
biomed devic servic
symptomat patient year year year american age aortic age sever sever symptomat etiolog s/ ssa primari etiolog pe patient yr severe/symptomat ssa pe patient yr yr severe/symptomat ssa pe patient consid high risk surgeri consid intermedi risk surgeri consid risk surgeri consid high risk surgeri consid intermedi risk surgeri consid risk surgeri tavr market opportun tavr market opportun aortic stenosi elderli diseas preval number candid transcathet aortic valv replac meta-analysi model studi canaccord genuiti estim -conserv assum preval old age euroheart survey primari reason age lv canccord genuiti primari research ew compani report investor day assum ou market europe/japan us figur tavi ww market share
biomed devic servic
edward lifesci averag implant center total asp ew ww tavi revenu ex growth averag total asp ww tavi revenu growth averag total asp ww tavi revenu growth player ww tavi revenu ww implant patient popul high player tavi ww revenu market lifesci implant averag implant total asp ew us revenu averag total asp total us revenu averag total asp us revenu player us revenu us implant address patient penetr us tavr market figur tavi eu/row market share
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
biomed devic servic
million except per share revenu incl stock total revenu gross oper expens incom pre-tax incom tax interest exp eitf add-back net incom share ep forma ex ia margin analysi gross margin pro sale sale y/i revenu growth growth growth incom pro forma incom forma ex-one-tim ia revenu includ impact foreign currenc translat exclud return reserv stock figur revenu model
biomed devic servic
heart valv aortic/mitr replacement/repairaort tavi sapien product royalti us total tavi mitral/trucuspid tmvr/re usous- total tmvr/re revenue- total transcathet surgic heart valv therapytissu repair surgic heart valv cardiac perfusion/cannula cardiac surgeri total surgic hv cs surgic valv consign total surgic hv/c revenu critic hemodynam pressur critic vascular catheter-bas angioscopi vascular total critic vascular total revenu pro forma total revenu figur revenu model part
biomed devic servic
